Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 2, 2024.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
There are several pending treatment decisions to come in the first half of 2024, ranging from neurological specialties in movement disorders, neuromuscular, headache and migraine, epilepsy, and much more. As there is so much happening constantly in the clinical drug pipeline, keeping up with the latest approvals might be a challenge. Here are a few critical FDA pending approvals with expected data readouts in 2024 that NeurologyLive® will have its eye on.
Sumaira Ahmed, the founder and executive director of the Sumaira Foundation, shared her patient perspective of Health Canada’s approval of inebilizumab in terms of its implications for patients and how it paves the way for future treatments in NMOSD. [WATCH TIME: 3 minutes]
The International Journal of MS Care is a peer-reviewed, multidisciplinary, open access journal and the official journal of the Consortium of MS Centers. The journal strives to be useful and pertinent to all who are part of an MS care team, including physicians, nurses, therapists, and more. As part of NeurologyLive's ongoing partnership with the CMSC, we're happy to spotlight some of the latest peer-reviewed articles published in IJMSC.
In this week's NeuroVoices Q&A, J. William Lindsey, MD, a professor in the department of neurology with McGovern Medical School at UTHealth Houston discussed outcomes of a recent study exploring the specificity of T cells in the spinal fluid of patients diagnosed with multiple sclerosis.
As part of our monthly clinician spotlight, NeurologyLive® highlighted rare disease medicine expert Paula Barreras, MD, a physician neurologist and neuroimmunologist at Cedars Sinai Medical Center. Barreras discussed her key responsibilities as a neurologist specializing in immune-mediated conditions, and the ways she balances clinical work, research, and education in her role.